Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach
Clinical and Translational Science · 2026-05 · 19 (5)
DOI: 10.1111/cts.70531 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 27.04.2026. Verfasst von Hanieh Shafaei Kachaei und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran. Hauptthemen laut MEDLINE: Renal Dialysis, Dietary Supplements, Fatty Acids, Omega-3, Inflammation. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilan University of Medical Sciences, Shahid Beheshti University.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is closely associated with systemic inflammation. This randomized controlled trial aimed to evaluate the effects of omega‐3 fatty acids supplementation on inflammatory markers in patients with CKD undergoing hemodialysis. Eligible participants with CKD receiving hemodialysis were randomly assigned to either an intervention group or a control group. The intervention group received three capsules of omega‐3 fatty acids (3 g/day) for two months, while the control group received placebo capsules containing medium‐chain triglyceride (MCT) oil. Inflammatory markers, including C‐reactive protein (CRP) and interleukin‐6 (IL‐6), were measured both before and after the interventions. The results showed that CRP levels increased from 9.86 ± 12.64 to 11.46 ± 22.23 mg/L in the intervention group and from 5.24 ± 9.01 to 5.61 ± 7.93 mg/L in the control group ( p = 0.11). Similarly, IL‐6 levels increased from 17.84 ± 14.08 to 81.82 ± 66.22 pg/mL in the intervention group and from 14.96 ± 18.41 to 56.73 ± 115.45 pg/mL in the control group ( p = 0.53). No statistically significant group differences were observed after adjusting for confounders such as age, sex, body mass index (BMI), smoking, dietary intake, and pre‐existing diseases. The study findings showed that a two‐month intake of omega‐3 fatty acids supplements did not have a significant impact on reducing the levels of inflammatory markers in CKD patients undergoing hemodialysis. Larger trials with longer durations are warranted. Study Highlights What is the Current Knowledge on the Topic? Omega‐3 fatty acids have anti‐inflammatory properties and are reported to be potentially beneficial in reducing inflammation associated with CKD, but the evidence regarding the effectiveness of omega‐3 supplements in reducing inflammatory markers in this population remains inconsistent. What Question did this Study Address? What is the effect of omega‐3 fatty acids supplementation for 2 months on CRP and IL‐6 levels in patients with CKD undergoing hemodialysis? What Does This Study Add to Our Knowledge? Contrary to previous studies, this study found that omega‐3 fatty acids supplementation did not significantly reduce CRP or IL‐6 levels compared with placebo over 2 months and that short‐term supplementation is not sufficient to reduce systemic inflammation in hemodialysis patients. How Might this Change Clinical Pharmacology or Translational Science? These findings suggest that short‐term omega‐3 fatty acids supplementation may not be sufficient in reducing inflammatory markers in CKD patients undergoing hemodialysis and highlight the need for larger‐scale clinical trials with different doses and longer durations to investigate nutritional or pharmacological strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran.
- Nutrition and Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Physiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
- Akhtar Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Division of Food Safety and Hygiene, Department of Environmental Health Engineering, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Saeid Doaei
Förderung
- Gilan University of Medical Sciences
- Shahid Beheshti University
Zitieren
APA
Shafaei Kachaei, H., Abbasi Mobarakrh, K., Azaryan, F., Torkaman, M., Askarpour, S. A., Harsini, A. R., Fahimzad, F. S., Mousavi Mele, M., Hoseinzadeh Liavoli, M., Masoomi Golujeh, N., Ataie Kashki, S., Khoshdooz, S., Doaei, S., Khosravi, M., & Gholamalizadeh, M. (2026). Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70531
Vancouver
Shafaei Kachaei H, Abbasi Mobarakrh K, Azaryan F, Torkaman M, Askarpour SA, Harsini AR, et al. Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70531
BibTeX
@article{ShafaeiKachaei2026,
author = {Shafaei Kachaei, Hanieh and Abbasi Mobarakrh, Khadijeh and Azaryan, Fatemeh and Torkaman, Mahdieh and Askarpour, Seyed Ali and Harsini, Asma Rajabi and Fahimzad, Fatemeh Sadat and Mousavi Mele, Mahdi and Hoseinzadeh Liavoli, Marziyeh and Masoomi Golujeh, Neda and Ataie Kashki, Sanaz and Khoshdooz, Sara and Doaei, Saeid and Khosravi, Masoud and Gholamalizadeh, Maryam},
title = {Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {5},
doi = {10.1111/cts.70531}
}
EUVIMED